Study of a cancer-killing virus injection for solid tumors
Treatments studied
Part of Cancer clinical trials.
This early-phase trial tests a cancer-killing virus (OTS-412) that is injected directly into tumors. It is for people with solid tumors that have not responded to standard treatments, including immunotherapy. The goal is to see if the virus can shrink or control the injected tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 or older and have a solid tumor cancer (like liver, skin, kidney, bladder, bile duct, head/neck, stomach, breast, colorectal, or MSI-high) that no longer responds to standard treatments.
- You have at least one tumor that a doctor can safely inject with a needle, either just under the skin or using an ultrasound. The tumor must be at least 1 cm wide and not near important blood vessels or organs.
- You have not received a virus-based cancer treatment (like Imlygic) before, and you haven't had other cancer treatments or experimental drugs in the last 4 weeks.
- Your overall health is reasonably good: you can still care for yourself (ECOG 0-2), have a life expectancy of at least 12 weeks, and your blood counts and organ function meet the required levels.
- You do not have uncontrolled brain tumors, active autoimmune disease, serious heart problems, or a weakened immune system (from HIV, high-dose steroids, or organ transplant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, OTS-412, which is a modified virus that may infect and kill cancer cells. It is given as an injection directly into a tumor. The study is for people with solid tumors that have not responded well to standard treatments.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
This trial tests an experimental therapy that combines a new drug (OVV-01) given intravenously and injected directly into tumors, along with another immunotherapy drug (AK112). It's for people with advanced solid tumors who have run out of standard options, and it aims to see if the combination can shrink tumors or slow their growth.
This study tests a new cancer treatment called OVV-01 that is injected directly into tumors or given through the vein. It's for patients with advanced solid cancers (like melanoma, lung, breast, or colon cancer) who have already tried at least two standard treatments without success.
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
Hear when a new Treatment-Refractory Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.